[go: up one dir, main page]

AU2002342858A1 - Human high-affinity antibody fragments for essential proteins of the hepatitis-c virus - Google Patents

Human high-affinity antibody fragments for essential proteins of the hepatitis-c virus

Info

Publication number
AU2002342858A1
AU2002342858A1 AU2002342858A AU2002342858A AU2002342858A1 AU 2002342858 A1 AU2002342858 A1 AU 2002342858A1 AU 2002342858 A AU2002342858 A AU 2002342858A AU 2002342858 A AU2002342858 A AU 2002342858A AU 2002342858 A1 AU2002342858 A1 AU 2002342858A1
Authority
AU
Australia
Prior art keywords
hepatitis
virus
antibody fragments
affinity antibody
human high
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002342858A
Inventor
Olga Artsaenko
Dieter Hausslinger
Tobias Heintges
Kathi Tessmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2002342858A1 publication Critical patent/AU2002342858A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C07K16/118—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2002342858A 2001-05-11 2002-05-13 Human high-affinity antibody fragments for essential proteins of the hepatitis-c virus Abandoned AU2002342858A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10123041.9 2001-05-11
DE10123041A DE10123041A1 (en) 2001-05-11 2001-05-11 New single-chain human antibody fragment, useful for treating or diagnosing hepatitis C virus infection, has affinity for an essential viral protein
PCT/EP2002/005227 WO2002093519A2 (en) 2001-05-11 2002-05-13 Human high-affinity antibody fragments for essential proteins of the hepatitis-c virus

Publications (1)

Publication Number Publication Date
AU2002342858A1 true AU2002342858A1 (en) 2002-11-25

Family

ID=7684487

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002342858A Abandoned AU2002342858A1 (en) 2001-05-11 2002-05-13 Human high-affinity antibody fragments for essential proteins of the hepatitis-c virus

Country Status (3)

Country Link
AU (1) AU2002342858A1 (en)
DE (1) DE10123041A1 (en)
WO (1) WO2002093519A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002337885B1 (en) 2001-10-16 2003-04-28 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Broadly cross-reactive neutralizing antibodies against human ummunodeficiency virus selected by Env-CD4-co-receptor complexes
EP1554392A4 (en) 2002-05-06 2007-08-08 Us Gov Health & Human Serv IDENTIFICATION OF WIDE-NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES WITH CROSS-REACTION USING SEQUENTIAL PLATE ADHESION METHOD OF ANTIGENS OF PHAGE PRESENTATION BANKS
EP1504034B1 (en) 2002-05-06 2012-12-12 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Identification of novel broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies
AU2004321500A1 (en) * 2003-09-29 2006-05-11 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunoglobulins with potent and broad antiviral activity
WO2006099747A1 (en) 2005-03-25 2006-09-28 National Research Council Of Canada Method for isolation of soluble polypeptides

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171782B1 (en) * 1987-11-18 2001-01-09 Chiron Corporation Antibody compositions to HCV and uses thereof
US6194140B1 (en) * 1990-04-04 2001-02-27 Chiron Corporation HCV NS3 protein fragments having helicase activity and improved solubility
US6190864B1 (en) * 1991-05-08 2001-02-20 Chiron Corporation HCV genomic sequences for diagnostics and therapeutics
DE19531226C1 (en) * 1995-08-24 1997-04-03 Immuno Ag Pharmaceutical compsn. for prevention or treatment of viral disease

Also Published As

Publication number Publication date
DE10123041A1 (en) 2002-11-28
WO2002093519A2 (en) 2002-11-21
WO2002093519A3 (en) 2003-10-30

Similar Documents

Publication Publication Date Title
AU2002338015A1 (en) Human CDR-grafted antibodies and antibody fragments thereof
AU2002349727A1 (en) Hepatitis E virus monoclonal antibodies or the binding fragments of it and the use thereof
AU2002312303A1 (en) Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
AU2002237195A1 (en) Recombinant poxvirus for chimeric proteins of the human immunodeficiency virus
AU2002300166A1 (en) Process for the Preparation of Peptides
NO20023445D0 (en) Process for the preparation of peptides
AU2002365269A1 (en) Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses
AU2002322082A1 (en) Pharmaceutical composition for the treatment of viral infection
AU2002342858A1 (en) Human high-affinity antibody fragments for essential proteins of the hepatitis-c virus
AU2002325169A1 (en) Pharmaceutical composition for the prophylaxis and/or treatment of virus diseases
AU2002341828A1 (en) Enhanced proteins and methods for their use
AU2002311620A1 (en) Methods of making and using expression constructs for the expression of recombinant proteins
AU2002362414A1 (en) Novel molecules of the hkid-1-related protein family and uses thereof
AU2002354363A1 (en) Method of activating protein
AU2002364757A1 (en) Peptides for the production of preparations for the diagnosis and therapy of autoimmun diseases
AU2003226907A1 (en) Method for the preparation of recombinant mammalian heparin-binding protein (hbp)
AU2002346056A1 (en) Viral proteins capable of binding lar
AU2003214721A1 (en) Fragments of apoptin
AU2002365148A1 (en) Human ras interacting protein
AU2002254595A1 (en) Method for enhancing the translation and expression of recombinant proteins
AU2002328413A1 (en) Method for Determining Target Protein of Medicament
AU2002235761A1 (en) Stabilization of antibodies or fragments thereof
AU2002258548A1 (en) Identification of the ikappabns protein and its products
AU2002347102A1 (en) Means for inhibition of the synthesis of viral proteins
AU2002326909A1 (en) Neurotransmission-associated proteins

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase